AstraZeneca PLC Stock Forecast for 2023 - 2025 - 2030
Updated on 04/01/2023
AstraZeneca PLC Stock Forecast and Price Target
AstraZeneca PLC has an average price target of £155.85 recently offered by four notable experts for 2023, which would represent a potential downside of approximately -98.61% from the last closing price in March, 2023 if reached. This potential increase is based on a high estimate of £212.85 and a low estimate of £80.54. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.
-98.61% Downside
AstraZeneca PLC Fair Value Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Price has grown in the last two years, jumping from £60.20 to £90.99 – an increase of 51.14%. In the following year, 0 experts forecast AstraZeneca PLC's Fair Value will decrease by 20.32%, to £72.50. In 2030, professionals predict that AstraZeneca PLC's Fair Value will decrease by 17.59%, to £74.98.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$154.95 | Buy/Sell | $181.05 | 16.49% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$343.42 | Buy/Sell | $333.19 | 16.48% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr967.50 | Buy/Sell | kr937.82 | 0.78% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$159.36 | Buy/Sell | $162.24 | 3.54% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$40.79 | Buy/Sell | $53.97 | 29.08% |
AstraZeneca PLC Revenue Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Revenue has grown in the last two years, jumping from £24.38B to £37.42B – an increase of 53.45%. In the following year, 0 experts forecast AstraZeneca PLC's Revenue will decrease by 22.04%, to £29.17B. In 2030, professionals predict that AstraZeneca PLC's Revenue will decrease by 18.95%, to £30.33B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
5
|
$106.38 | Buy/Sell | $99.57 | 10.92% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | Buy/Sell | CHF103.75 | 9.89% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$101.26 | Buy/Sell | $121.44 | 23.44% |
.jpg)
AstraZeneca PLC Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, AstraZeneca PLC's Dividend per Share has increased by 2.50%, going from £2.80 to £2.87. According to 0 major analysts, AstraZeneca PLC's Dividend per Share will fall by 1.63% in the next year, reaching £2.82. Professionals believe that By 2030, AstraZeneca PLC's Dividend per Share will fall to £2.82– a 1.57% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$69.31 | Buy/Sell | $80.99 | 19.75% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$241.75 | Buy/Sell | $268.00 | 14.99% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$80.62 | Buy/Sell | $90.05 | 6.67% |
AstraZeneca PLC Free Cash Flow Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's Free Cash Flow has increased by 144.82% In the last two years, going from £1.99B to £4.87B. According to 0 analysts, AstraZeneca PLC's Free Cash Flow will fall by 30.20% in the next year, reaching £3.40B. Professionals believe that By 2030, AstraZeneca PLC's Free Cash Flow will fall to £3.69B – a 24.28% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
8
|
$288.30 | Buy/Sell | $231.47 | -21.59% |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
10
|
171.55€ | Buy/Sell | 208.74€ | 22.41% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$83.00 | Buy/Sell | $87.30 | 6.02% |
AstraZeneca PLC Net Income Forecast for 2023 - 2025 - 2030
In the last two years, AstraZeneca PLC's Net Income has gone down from £1.34B to £112.00M – a 91.61% drop. For next year, the 0 analysts predict Net Income of £2.15B, which would mean an increase of 1816.30%. Over the next nine years, the pros' prediction is Net Incomeof £402.18B, which would mean a nine-year growth forecast of 358988.24%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$247.48 | Buy/Sell | $268.00 | 11.12% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.43k | Buy/Sell | £16.95 | -98.87% |
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$153.58 | Buy/Sell | $0.00 | 39.02% |
AstraZeneca PLC EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, AstraZeneca PLC's EBITDA has grown, increasing from £5.65B to £8.37B – a growth of 48.27%. In the following year, 0 experts forecast that AstraZeneca PLC's EBITDA will decrease by 18.32%, to £6.84B. In 2030, professionals predict that AstraZeneca PLC's EBITDA will decrease by 15.98%, to £7.04B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
58.72€ | Buy/Sell | 74.54€ | 28.58% |
| BAS Stock Forecast | BASF | Hold |
11
|
48.36€ | Buy/Sell | 53.50€ | 13.73% |
AstraZeneca PLC EBIT Forecast for 2023 - 2025 - 2030
In the last two years, AstraZeneca PLC's EBIT has grown by 46.16%, from £3.13B to £4.57B. 0 analysts predict AstraZeneca PLC's EBIT will decrease by 14.35% in the next year, reaching £3.91B. By 2030, professionals predict that AstraZeneca PLC's EBIT will decrease by 12.65%, to £3.99B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | Buy/Sell | ¥0.00 | 36.03% |
| LONN Stock Forecast | Lonza Group Ltd | Outperform |
16
|
CHF457.90 | Buy/Sell | CHF756.46 | 71.98% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$278.03 | Buy/Sell | $322.44 | 16.89% |
AstraZeneca PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030
AstraZeneca PLC's EPS has grown in the last two years, jumping from £3.50 to £5.29 – an increase of 51.14%. In the following year, 0 experts forecast AstraZeneca PLC's EPS will decrease by 20.32%, to £4.22. In 2030, professionals predict that AstraZeneca PLC's EPS will decrease by 17.59%, to £4.36.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$150.09 | Buy/Sell | $0.00 | 32.12% |
| ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$232.55 | Buy/Sell | $254.08 | 7.29% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
.jpg)